C-reactive protein risk prediction: Adding cardiac hypertrophy to the list

American Journal of Kidney Diseases

Volumn 40, Issue 6, 2002, Pages 1340-1341

  Wanner, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

BLOOD LEVEL; DIALYSIS; DISEASE COURSE; EDITORIAL; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; INCIDENCE; INFLAMMATION; OXIDATIVE STRESS; PLASMA VOLUME; RISK FACTOR; VASCULAR ACCESS;

EID: 0036896955     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.37389     Document Type: Article

References (16)

1. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648-658, 1999
2. Stenvinkel P, Wanner C, Metzger T, et al: Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage. Kidney Int 62:1791-1798, 2002
3. Shoji T, Nishizawa Y, Kawagishi T, et al: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9:1277-1284, 1998
4. Zoccali C, Benedetto FA, Maas R, et al: Asymmetric dimethylarginine, C-reactive protein, and carotid intimamedia thickness in end-stage renal disease. J Am Soc Nephrol 13:490-496, 2002
5. Kronenberg F, Neyer U, Lhotta K, et al: The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: A prospective follow-up. J Am Soc Nephrol 10: 1027-1036, 1999
6. Pecoits-Filho R, Barany P, Lindholm B, Heimburger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 17:1684-1688, 2002
7. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW: The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 58:346-352, 2000
8. Koch M, Kuthuhn B, Trenkwalder E, et al: Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 8:1889-1898, 1997
9. Park CW, Shin YS, Kim CM, et al: Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 40:1230-1239, 2002
10. Caglar K, Peng Y, Pupim LB, et al: Inflammatory signals associated with hemodialysis. Kidney Int 62:1408-1416, 2002
11. Zoccali C, Mallamaci F, Maas R, et al, on behalf of the CREED Investigators: Left ventricular hypertrophy, cardiac remodeling and asymetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62:339-345, 2002
12. Foley RN, Parfrey PS, Morgan J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335, 2000
13. London GM, Pannier B, Guerin AP, et al: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12:2759-2767, 2001
14. Gunnel J, Yeun JY, Depner TY, Kaysen GA: Acutephase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33:63-72, 1999
15. Amann K, Breitbach M, Ritz E, Mall G: Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9:1018-1022, 1998
16. Koenig W, Torzewski J: C-reactive protein and atherosclerosis: Quo vadis? Ital Heart J 2:801-803, 2001